The Checkmate 227 study demonstrated that treatment with combination ipilimumab–nivolumab in patients with non‐small cell lung cancer was associated with a significant advantage in OS compared with chemotherapy, regardless of PD‐L1 expression. The gene discussed is CD274; the disease is lung cancer.